M ali g nant m elano m a ce ll s possess a unique bi ochemi cal pathway that converts L-3, 4-dihydro xy ph en ylalaninc (Ld o pa) to th e biopig m ent m elanin. Selective cy totoxic inco rpo ration o f exogenous L-d opa into m elano m a cell s in vivo may prov id e a m eans of desig nin g specific chemotherapeutic agents useful in th e trea tm ent of thi s disease. U sin g the Hardin g-Passey murin e m elanotic tum o r model , a preferential uptake of [ 3 H)L-dopa by th e tumor was characterized. Following pretreatment of the tum or-bearin g m.icc with no nradioactive L-dopa , a sig nifi cant enh ancement L -3,4-Dihydroxyphenylalanine (L-dopa) is a prec ursor in the bi osynthesis of mel anin [1 ,2]. M ali g n an t melanoma , still a therapeuti ca ll y res istant tum o r, possesses thi s unique biochemical path way for the conversion of L-d o pa to melanin [3 ,4]. Severa l inves ti ga to rs have used this special pathway as a m ea ns to design m o re effecti ve chem o th erapeutic age nts useful in the t re atment of this di sease. Wi ck et al [51 showed a selec tiv e cytotoxi c in co rpo ration of L-d o pa by pigm ented m elanoma cell s in vitro . Blois and Kallman [6] demonstrated a hi g hl y selec tiv e uptake of radioa ctive L-dop a into a spontaneo usly arising murine melano ma. Recentl y, usin g the Harding-Passey murin e melano ma model, o ur studi es and o thers were able to show an extensive loca liza ti o n of L-do pa in the tumor and in th e adren al g lands [7, 8]. In this communi catio n we describe a preferenti al localization of ( 3 H] L-do pa in the H ardin g-Passey tum o r following pretreatment of tum o r-bearin g mice with nonradi oactive L-dopa, and contrast it to th e conco mitant ti ss ue distributio n and retentio n of this radi oactive agent in th e control animals.
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MATERIALS AND METHOD S
Experitnental Procedure CDF 1 mice used in this study were approx imately 3 months of age and weig hed o n ave rage 25 g. H ardin g-P assey pi g m ented melano m a tum or cell s, prepared from tum o r transplant, were seria ll y p assaged s.c. in CD F 1 ti ss ues, includin g brain , lun g, splee n , adrena l g lands, kidn ey. muscles, an d tum o r, were rem oved . Each s pecim en was weig hed and burned in a Packard Tri-ca rb oxidizer. The radi oacti vit y w as m eas ur ed in a liquid scintillati o n counter and fo r each ti ss ue the co unts were ex pressed in cpm / m g of we t ti ss ue weight.
Statistical Analysis The objective w as to determ ine any di~ fercnce in the tim e co urse for each organ site between the cont rol and th e ex perim ental g roups. For each site th e uptake and retenti o n of f 3 H]L-d o pa were approximated as an exponential ti m e co urse. The linear form of this m odel is: ,.j E A uc is co mputed rro m n.:g r<. :ssion fa ror 1 3 1-t IL-dopa kinc.:tics. Nut~ th l' hi ghes t relati ve cnhnn ct mcnt inJ t·x fo r rumor.
of tum or with nonradioa ctive L-dopa ma y provide a m ea ns of studyin g and testing new modalities of therap y in this, otll: o f the most agg ress ive forms of ca n ce r.
DI SCUSS ION
In the present st udy the Harding-Passey pi g memed mel an o m a tumor was ch ose n JS a m o del bccause of its similarity to human melan o nia w ith respect to irs response to chctnorherapy. T h e H arding-l:'asscy mctmoma shows a response rate of 25% to dacarbazim: treatm ent, whi le other experime n ta l melanom a tumors , e .g. , the 1:31 6 pigmented melan otic tumor, do not res pond as we ll to d aca rba zine 1111. Studies usin g radioacti ve melanin precurso r as a tool h ave shown th at th e co n centrat io n of radioa cti vit y found in various anima l melanom a tumors may vary !6,7, 12 1. T he ava ilable d a ta suggest that this relative difference in in creased uptake and co n ce n tration o f radioa ctivit y in th e tumor is related to th e rate of m e lanin synthes is . 13lois and Kallman [6 1 fo und th at the radi oactiv it y co ncentratio n was p rimarily located in the mel anin poly m er and n ot in the remainder of the rumor cell. Takahashi and Fit zp atri ck !1 2 ] found an absen ce o f stable d opa in the h ydroly sates of melan osomes from deep ly pi g mcmed B 16 melanoti c tumors, but di scove red larg e co n centrati o ns o f stab le dopa in t he Hardin g-l'assc y melanoma. This wou ld tmd to also s uppo rt th e proposa l of Bl o is and Kallm an !6 1 th at the.: uptake.: and in co rporati o n o f prc.: curso rs such as dopa arc pro portiona l to the ra te of mel anin sy nthesis in the tum or.
While.: mo st repo rts have shown that in crea s in g melani za ti o n and in co rporatio n of agents that enhance pigmentation can indu ce se lective. : toxicity to melanoma ce ll s in vitro [3-51, s tudies by Parso ns and Morriso n !1 3 1 su ggest that this toxi cit y m a y be closely related to DNA dama g e . Although the pn:cisc mech ani s m of this DNA dama ge is n or known, the selective preferential uptake of d o pa and th e resultin g toxicity to mammal ian cells do cs corn: late we ll w ith mel ani zat ion IS \. In additi o n , no inhibition by dopa o r dopamine agonists and antagon ists in ame lanotic B16 cell s ha s been obse rved \1 4] . Table I ) fo ll owing prctrea tmcllt w ith un labeled dop a also co nfirm s the sa me findin g of another rep o rt of mel anoma tum o rs in h a m s ters and in a lbino mi ce 17 !. Altern a tiv ely . L-d o p a in co rpo rat io n of mel an oma m ay also be enhan ced b y d opa de ca rboxy lase inhibitio n. Wicket al!1 7 ! h ave sh ow n that in the prese nce o f a potellt de carbo xy lase inhibito r , se rum le vel of L-dopa co uld be elevated, th e reb y an enhan cement of L-d opa in co rp o rati o n into m ela noma was achi eved and the diversi on of labe l into adrena l g land was g reatl y obviated. In o ur stu d y of ti ss u e levels o f L-do pa in corpora ti o n , no ser um to organ-specific activ ity was dete rmined. A lt ho ug h the specif1 c me ch ani s m of L-dopa acti on resu ltin g in su ch a ph en o menon ha s n o t ye r been resolved, our findings ma y have an impli cation for the us e fuln ess of L-dopa in human m alig n ant melan o ma therapy !I tl !.
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